AMCP webinar that reviewed the provisions contained in the draft 2020 CMS Medicare Part D Call Letter that was released by the Centers for Medicare and Medicaid Services (CMS) on January 30, 2019.
AMCP shares the committee’s concerns about the unsustainable burden of high drug pricing on patients and providers and has been working with stakeholders to educate Congress on ways that AMCP pharmacists, physicians, and nurses can improve health outcomes while lowering costs.
AMCP expresses strong support for S. 340, the “Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act,” bipartisan legislation to increase competition and patient access to safe and affordable generic and biosimilar medicines. AMCP is pleased it was reintroduced into legislation in the 116th Congress on February 5, 2019.
On Dec 12, 2018 The Food and Drug Administration (FDA) issued a new proposal to amend its regulation that defines “biological product” to incorporate changes made by the Biologics Price Competition Act of 2009 (BPCI Act).